Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

888
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
888
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

728
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
728
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.5K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.2K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.2K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.5K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.5K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

2.0K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Human Cytomegalovirus exposure with tuberculosis disease in South African adults with presumptive tuberculosis.

PLOS global public health·2026
Same author

Decision-making for indoor residual spraying in the post-elimination phase of visceral leishmaniasis in Nepal.

PLoS neglected tropical diseases·2026
Same author

Genomic characterization of <i>Klebsiella pneumoniae</i> isolates from sepsis patients in Ethiopian tertiary hospitals: a multicenter cross-sectional study.

Frontiers in microbiology·2026
Same author

Mapping the last mile: Micro-stratification for sustained visceral leishmaniasis elimination in Bangladesh.

PLoS neglected tropical diseases·2026
Same author

Visceral leishmaniasis & HIV co-infection in Bangladesh: Investigating prevalence and policy recommendations.

Journal of infection and public health·2026
Same author

Maternal infection at delivery and risk of stillbirth and early neonatal death: nested case-control studies in East African pregnancy cohorts.

BMC pregnancy and childbirth·2026

Related Experiment Video

Updated: Apr 6, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Towards host-directed therapies for tuberculosis.

Alimuddin Zumla1, Markus Maeurer2,

  • 11] Division of Infection and Immunity at the University College London (UCL), London, UK and National Institute of Health Research's Biomedical Research Centre UCL Hospitals National Health Service Foundation Trust, Royal Free Campus, 2nd Floor, Rowland Hill Street, London NW3 2PF, UK. [2] Department of Microbiology, University College London Hospitals NHS Foundation Trust, London, UK.

Nature Reviews. Drug Discovery
|July 18, 2015
PubMed
Summary
This summary is machine-generated.

New host-directed therapies complement traditional tuberculosis treatments targeting Mycobacterium tuberculosis. This approach aims to improve patient outcomes by modulating the host

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Related Experiment Videos

Last Updated: Apr 6, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Area of Science:

  • Infectious Diseases
  • Immunology
  • Pharmacology

Background:

  • Tuberculosis (TB) treatment relies on antimicrobial drugs targeting Mycobacterium tuberculosis.
  • Drug resistance necessitates novel therapeutic strategies.
  • Host-directed therapies (HDTs) offer a complementary approach to TB management.

Purpose of the Study:

  • To explore the development and potential of adjunct host-directed therapies for tuberculosis.
  • To complement existing antimicrobial drug regimens.
  • To improve global tuberculosis treatment outcomes.

Main Methods:

  • Review of current research on host-directed therapies for tuberculosis.
  • Analysis of mechanisms by which HDTs modulate host immune responses.
  • Evaluation of preclinical and clinical data on HDT candidates.

Main Results:

  • HDTs aim to modulate the host immune response rather than directly targeting the pathogen.
  • Potential benefits include enhanced pathogen clearance and reduced inflammation.
  • Several HDT candidates are under investigation for their efficacy and safety.

Conclusions:

  • Host-directed therapies represent a promising complementary strategy to conventional anti-tuberculosis drugs.
  • Further research and clinical trials are crucial for the successful implementation of HDTs.
  • HDTs could play a significant role in combating tuberculosis, especially drug-resistant strains.